The 2015 ICH guidelines did not include a Class I recommen- dation for reversal of newer anticoagulant agents such as dabi- gatran, rivaroxaban, or apixaban. Thus, the writing group felt that a specific performance measure should not be developed at this time. However, this is an important issue for future guideline and performance measure updates. Venous thromboembolism prophylaxis exists as a mea- sure for patients with ICH in the CDC s Paul Coverdell National Acute Stroke Program and is an NQF-endorsed measure. An analogous performance measure is present in the AHA/ASA ischemic stroke performance measures that allows the use of anticoagulant medications or mechanical devices to meet the measure. For ICH, the use and optimal timing of anticoagulant medications remain without Class I recommendations. However, the use of pneumatic compres- sion devices on the day of hospital admission is a Class I rec- ommendation from the 2015 AHA/ASA ICH guidelines and is required to successfully meet this performance measure. For purposes of harmonization with analogous performance measures from other groups, use of pneumatic compression devices on day 0 (admission day) or day 1 of hospitalization is considered acceptable. Three measures in this ICH performance measure set are identical to those in theAHA/ASA ischemic stroke measure set. They relate to dysphagia screening and rehabilitation services. All 3 of these measures derive from an independent Class I rec- ommendation in the 2015AHA/ASA ICH guidelines. However, these are also issues that generally apply to all stroke patients, Hemphill et al Performance Measures for ICH e249 and this factored significantly into the writing group s delib- erations on whether to draft entirely independent and unique performance measures on these topics for ICH or to consider whether the existing performance measures on these topics should be adopted for ICH. 